Olathe, Kan., September 15, 2011 – Novita Therapeutics, LLC (Novita) announced today that the Kansas Bioscience Authority (KBA) has made a $600,000 equity investment in Novita.

"During the past year we have made tremendous progress and are rapidly advancing the development of our first product," said F. Nicholas Franano, M.D., President and CEO of Novita. "This financing will allow us to continue to move forward without interruption."

"Novita has shown the drive and initiative necessary to get a new company started and financed," said KBA interim President and CEO David Vranicar. "We have followed Novita closely and are excited to be a partner in helping them move forward. We believe Novita will be an excellent investment that will bring new, high-paying jobs to the state of Kansas."

About Novita Therapeutics
Novita Therapeutics, LLC is a privately held biopharmaceutical and medical device company headquartered in Olathe, Kansas. For additional information, please visit www.novitatherapeutics.com.

About the KBA
The Kansas Bioscience Authority (KBA) was created by the Kansas Economic Growth Act of 2004 with the sole purpose of advancing Kansas' leadership in bioscience. The KBA is the state's largest-ever commitment to expanding Kansas' research capabilities, promoting innovation, and encouraging company formation that will create high-paying jobs for generations to come. For more information visit www.kansasbioauthority.org.